Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Hematology

Medical Treatments and JAK Inhibitors

At a Glance

Myelofibrosis treatment is tailored to risk, symptoms, blood counts, anemia, and spleen size. JAK inhibitors can control an enlarged spleen and whole-body symptoms but are not curative; anemia, low platelets, safe ruxolitinib tapering, clinical trials, and transplant eligibility also guide care.

Medical treatment for myelofibrosis (MF) is risk-adapted, meaning your doctors look at your risk score and symptoms to decide the best path forward [1]. If you have “low-risk” disease and no symptoms, your team may recommend “watchful waiting”—monitoring your health closely without starting intensive therapy [2]. However, for most patients with intermediate or high-risk disease, the focus shifts to managing the overactive JAK-STAT pathway [3]. It is important to note that JAK inhibitors generally control spleen and constitutional symptoms, but they are not curative and do not replace assessment for an allogeneic stem cell transplant in eligible patients.

The Four JAK Inhibitors: A Tailored Approach

The most common medical treatments for MF are JAK inhibitors. These drugs work by blocking the “stuck” switch in your bone marrow cells [4]. Because each drug behaves slightly differently, your doctor will choose one based on your specific blood counts and symptoms [5].

Medication Typical Use Case Key Considerations
Ruxolitinib First-line treatment for an enlarged spleen and whole-body symptoms [1]. Can cause or worsen anemia and low platelets; must be managed carefully if stopping [6][7].
Fedratinib Often used after ruxolitinib or for specific patient profiles [8]. Requires checking and correcting thiamine (Vitamin B1) levels. Watch for confusion, vision changes, or trouble walking, which are signs of severe encephalopathy [9][10].
Pacritinib Specifically designed for patients with severe thrombocytopenia (platelets below 50,000/µL) [11]. Can be used when other JAK inhibitors are unsafe due to low blood counts [12][13].
Momelotinib Specifically for patients with significant anemia or transfusion needs [14]. Helps manage spleen and symptoms while potentially improving red blood cell counts [15][16].

Important Safety: The Ruxolitinib Taper

If you are taking ruxolitinib, it is critical that you do not change your dose or stop taking it on your own. Abruptly stopping this medication can lead to a withdrawal syndrome, where your symptoms return very rapidly and severely, sometimes causing dangerous levels of inflammation in the body [6][17]. Contact your hematology team immediately for an individualized plan if you need to pause treatment. If an urgent emergency requires stopping, your clinicians will safely manage the interruption [7].

Managing Anemia and Low Counts

Anemia is one of the most challenging aspects of myelofibrosis. While momelotinib is a JAK inhibitor that helps with anemia, other strategies may be used instead of or alongside your main treatment [18]:

  • ESAs (Erythropoiesis-Stimulating Agents): These are injections that signal your body to make more red blood cells [19].
  • Danazol: A synthetic hormone that can help some patients improve their hemoglobin levels [15].
  • Luspatercept: While currently approved for other conditions like myelodysplastic syndromes, this “erythroid maturation agent” is being actively studied in MF clinical trials to see if it can reduce the need for blood transfusions [20][21].

The Role of Clinical Trials

Because myelofibrosis is rare and complex, many of the newest and most promising treatments are only available through clinical trials. These trials may explore new “combination” therapies—using a JAK inhibitor plus another drug—to see if they can work better than one drug alone [22]. Discussing clinical trials with your care team can provide access to emerging therapies that are not yet widely available [22].

Common questions in this guide

How are myelofibrosis treatments chosen?
Treatment is tailored to your disease risk, symptoms, blood counts, anemia, platelet levels, and spleen size. People with low-risk disease and no symptoms may be monitored, while other patients may need a JAK inhibitor or another treatment.
What are the four JAK inhibitors used for myelofibrosis?
The four commonly used JAK inhibitors are ruxolitinib, fedratinib, pacritinib, and momelotinib. Doctors choose among them based on your symptoms and blood counts; pacritinib is especially used when platelets are very low, and momelotinib may help when anemia or transfusion needs are significant.
Why can't I stop ruxolitinib suddenly?
Stopping ruxolitinib abruptly can cause a withdrawal syndrome in which symptoms return quickly and severe inflammation may develop. Do not change the dose or stop it on your own; contact your hematology team so they can plan a safe taper or interruption.
What should I know before taking fedratinib?
Your care team should check your thiamine, or vitamin B1, level and correct a deficiency before treatment. Tell the team promptly about confusion, vision changes, or trouble walking because these can be warning signs of a serious brain-related reaction.
Can a JAK inhibitor cure myelofibrosis?
JAK inhibitors can reduce an enlarged spleen and improve whole-body symptoms, but they generally control the disease rather than cure it. If you may be eligible, your team should still discuss whether a donor stem cell transplant is appropriate.
Are clinical trials available for myelofibrosis?
Clinical trials are studying newer approaches, including combinations of a JAK inhibitor with another drug and treatments such as luspatercept for anemia. Ask your care team whether a trial fits your blood counts, symptoms, prior treatment, and location.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on myelofibrosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which of the four JAK inhibitors is most appropriate for my specific blood counts and spleen size?
  2. 2.If we start ruxolitinib, what is the plan for monitoring my hemoglobin, and at what point would we consider switching to an anemia-focused treatment like momelotinib?
  3. 3.Before starting fedratinib, will my thiamine levels be checked and corrected if low?
  4. 4.Am I a candidate for any clinical trials involving newer therapies like luspatercept or other combination treatments?
  5. 5.If I ever need to stop my medication for a procedure or side effect, how will we manage the tapering process to avoid a withdrawal syndrome?

References

References (22)
  1. 1

    Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

    Barbui T, Tefferi A, Vannucchi AM, et al.

    Leukemia 2018; (32(5)):1057-1069 doi:10.1038/s41375-018-0077-1.

    PMID: 29515238
  2. 2

    Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management.

    Tefferi A

    American journal of hematology 2018; (93(12)):1551-1560 doi:10.1002/ajh.25230.

    PMID: 30039550
  3. 3

    How I individualize selection of JAK inhibitors for patients with myelofibrosis.

    Masarova L, Chifotides HT

    Blood 2025; (145(16)):1724-1737 doi:10.1182/blood.2023022415.

    PMID: 39357058
  4. 4

    JAK2 V617F as a diagnostic and prognostic biomarker in myeloproliferative neoplasms.

    Bhat AA, Fuloria S, Thapa R, et al.

    Clinica chimica acta; international journal of clinical chemistry 2026; (590()):121116 doi:10.1016/j.cca.2026.121116.

    PMID: 42176929
  5. 5

    Managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors.

    De Fazio L, Molica M, Simio C, Rossi M

    Leukemia & lymphoma 2026; (67(6)):1257-1267 doi:10.1080/10428194.2026.2655442.

    PMID: 41982071
  6. 6

    Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.

    Arana Yi C, Tam CS, Verstovsek S

    Future oncology (London, England) 2015; (11(5)):719-33 doi:10.2217/fon.14.272.

    PMID: 25757677
  7. 7

    Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.

    Devos T, Selleslag D, Granacher N, et al.

    Hematology (Amsterdam, Netherlands) 2022; (27(1)):23-31 doi:10.1080/16078454.2021.2009645.

    PMID: 34957926
  8. 8

    Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.

    Harrison CN, Mesa R, Talpaz M, et al.

    The Lancet. Haematology 2024; (11(10)):e729-e740 doi:10.1016/S2352-3026(24)00212-6.

    PMID: 39265613
  9. 9

    Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.

    Bewersdorf JP, Jaszczur SM, Afifi S, et al.

    Cancer management and research 2019; (11()):10777-10790 doi:10.2147/CMAR.S212559.

    PMID: 31920387
  10. 10

    Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.

    Talpaz M, Kiladjian JJ

    Leukemia 2021; (35(1)):1-17 doi:10.1038/s41375-020-0954-2.

    PMID: 32647323
  11. 11

    New approaches to tackle cytopenic myelofibrosis.

    Reynolds SB, Pettit K

    Hematology. American Society of Hematology. Education Program 2022; (2022(1)):235-244 doi:10.1182/hematology.2022000340.

    PMID: 36485113
  12. 12

    Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.

    Gerds AT, Savona MR, Scott BL, et al.

    Blood advances 2020; (4(22)):5825-5835 doi:10.1182/bloodadvances.2020003314.

    PMID: 33232476
  13. 13

    Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.

    Verstovsek S, Mesa R, Talpaz M, et al.

    Haematologica 2022; (107(7)):1599-1607 doi:10.3324/haematol.2021.279415.

    PMID: 34551507
  14. 14

    Momelotinib: Mechanism of action, clinical, and translational science.

    Vlasakakis G, McCabe MT, Ho YL, et al.

    Clinical and translational science 2024; (17(8)):e70018 doi:10.1111/cts.70018.

    PMID: 39189872
  15. 15

    Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.

    Verstovsek S, Gerds AT, Vannucchi AM, et al.

    Lancet (London, England) 2023; (401(10373)):269-280 doi:10.1016/S0140-6736(22)02036-0.

    PMID: 36709073
  16. 16

    Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib.

    Harrison CN, Mesa R, Talpaz M, et al.

    Clinical lymphoma, myeloma & leukemia 2025; (25(3)):199-211 doi:10.1016/j.clml.2024.10.001.

    PMID: 39516087
  17. 17

    Cardiac Tamponade-A Rare Manifestation of Ruxolitinib Discontinuation Syndrome: A Case Report.

    Hamid S, Bennet R, Yao J, Wong J

    Case reports in cardiology 2026; (2026()):8854255 doi:10.1155/cric/8854255.

    PMID: 42088844
  18. 18

    Targeted treatment of anemia in myelofibrosis and the impact of JAK inhibitors.

    Al Noumani I, Harrison C

    Expert opinion on pharmacotherapy 2026; (27(8)):657-668 doi:10.1080/14656566.2026.2671877.

    PMID: 42101916
  19. 19

    The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.

    McMullin MF, Harrison CN, Niederwieser D, et al.

    Experimental hematology & oncology 2015; (4()):26 doi:10.1186/s40164-015-0021-2.

    PMID: 26380150
  20. 20

    Emerging Pathogenetic Mechanisms and New Drugs for Anemia in Myelofibrosis and Myelodysplastic Syndromes.

    Gangat N, Tefferi A

    American journal of hematology 2025; (100 Suppl 4()):51-65 doi:10.1002/ajh.27659.

    PMID: 40056069
  21. 21

    Transfusion Independence Achieved with Combination Fedratinib and Luspatercept in an Elderly Man with Heavily Pretreated Intermediate-2 Risk Primary Myelofibrosis.

    Yun NK, Alrifai T, Miller IJ, Shammo JM

    Case reports in oncology 2022; (15(1)):126-132 doi:10.1159/000521889.

    PMID: 35350804
  22. 22

    Treatment of anemia in myelofibrosis: focusing on novel therapeutic options.

    Arslan Davulcu E, Oğuz MB, Kılıç E, Eşkazan AE

    Expert opinion on investigational drugs 2024; (33(1)):27-37 doi:10.1080/13543784.2023.2294324.

    PMID: 38073183

This page is for informational purposes only and does not constitute medical advice. Your hematology team should choose and monitor your myelofibrosis treatment, including any JAK inhibitor taper or transplant evaluation.